Samsung Biologics Co. on Wednesday reported its third-quarter net income of 264.5 billion won (US$191.3 million), up 10 percent from a year earlier.

The company said in a regulatory filing that operating income for the July-September period rose 6.3 percent on-year to 338.6 billion won. Sales increased 14.8 percent to 1.18 trillion won.

The earnings beat market expectations. The average estimate of net profit by analysts stood at 251.3 billion won, according to a survey by Yonhap Infomax, the financial data firm of Yonhap News Agency.

Source: Yonhap News Agency